Donor heart preservation with a novel hyperpolarizing solution: Superior protection compared with University of Wisconsin solution  by Hoenicke, Eric M. et al.
Extending donor heart preservation time would offer
several advantages. Surgical results would likely
improve because it has been demonstrated with present
solutions that cold ischemic times inversely correlate
with postoperative survival.1 It also would allow for
One of the most significant limitations in heart trans-plantation is the relatively short preservation time
that current preservation solutions offer. Safe organ
preservation can be maintained for only 4 hours.
Objectives: A donor heart preservation solution was designed to use hyper-
polarized arrest with the adenosine triphosphate–sensitive potassium-chan-
nel opener pinacidil. This solution contained concentrations of potassium,
sodium, calcium, magnesium, lactobionate, and the buffer histidine specifi-
cally chosen to minimize intracellular calcium accumulation associated with
prolonged ischemia.
Methods: Twenty-four rabbit hearts were randomly assigned to receive 1 of
3 preservation solutions in a crystalloid-perfused Langendorff model: (1)
prototype solution containing a 0.5 mmol/L concentration of pinacidil, (2)
prototype solution without pinacidil as control, and (3) University of
Wisconsin solution. Thirty minutes of initial perfusion preceded baseline
data acquisition. Data comprised left ventricle pressure-volume curves gen-
erated by inflating an intraventricular latex balloon. After cardioplegic
administration, hearts underwent 4 hours of hypothermic storage, followed
by 60 minutes of reperfusion and postischemic data acquisition.
Results: Postischemic developed pressure was better preserved by pinacidil
solution (92.4% ± 4.5%) than by the control (74.9% ± 3.4%, P = .01) and
University of Wisconsin solutions (66.7% ± 5.1%, P = .001). Diastolic neg-
ative dP/dT was better preserved by pinacidil solution (104.4% ± 10.2%)
than by the control (80.2% ± 4.2%, P = .034) and University of Wisconsin
solutions (71.7% ± 7.0%, P = .015). Diastolic compliance, expressed as
baseline/postischemic diastolic slope ratios, was more poorly preserved by
University of Wisconsin solution (0.67 ± 0.07) than by the pinacidil (0.88 ±
0.05, P = .041) and control solutions (0.87 ± 0.05, P = .021). Postischemic
coronary flow was higher in hearts exposed to pinacidil solution (77.8% ±
3.0%) than in those exposed to the control (66.8% ± 2.4%) and University of
Wisconsin solutions (70.9% ± 4.0%, P = .07).
Conclusions: The superiority of the pinacidil solution in this experiment
demonstrated that hyperpolarized arrest with potassium-channel openers
improves donor heart preservation when administered in a novel histidine-
buffered lactobionate-enriched vehicle. (J Thorac Cardiovasc Surg
2000;120:746-54)
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completion of HLA tissue typing, which currently
takes approximately 8 hours. This is important because
long-term survival after heart transplantation is associ-
ated with HLA compatibility.2 Finally, extension of the
tolerable cold ischemic time would also expand the
procurement area for each heart transplant institution
and potentially change the status of the operation from
emergency to urgent.
All current strategies of long-term preservation for
heart transplantation involve the use of hypothermic,
hyperkalemic, cardioplegic solutions. These solutions
rapidly induce depolarized arrest of the donor heart by
means of a rapid increase in extracellular potassium.
However, depolarized arrest is associated with ionic
and metabolic imbalances that have been shown to lead
to arrhythmias, abnormal regulation of intracellular
second messengers, activation of adenosine triphos-
phate (ATP)–wasting cytosolic and membrane-bound
enzyme systems, ischemia-reperfusion injury, and
myocyte swelling.3 One of the pathophysiologic
processes considered to be responsible for these seque-
lae has been intracellular calcium accumulation.4
Depolarized arrest leads to intracellular calcium accu-
mulation by 3 distinct but interrelated mechanisms.4 As
the membrane becomes depolarized, voltage-sensitive
calcium channels open, activating an inward calcium
window current. Intracellular sodium concentration also
increases as the sodium window current is activated.
This increased cytosolic sodium concentration leads to
intracellular calcium accumulation through activation
of the sodium-calcium exchanger. The third mechanism
results from cytosolic calcium-induced calcium release
from the sarcoplasmic reticulum.
Our laboratory has proposed that adopting an alter-
native strategy of hyperpolarized arrest may alleviate
many of these untoward sequelae.5-7 To hyperpolarize
the cell membrane, we have administered drugs that
open ATP-sensitive potassium channels. These potassi-
um-channel openers have been shown to be superior or
equivalent to depolarized arrest during both short and
long periods of global ischemia.5-7 Other laboratories
have corroborated our findings that hyperpolarized
arrest may be superior to depolarized arrest for
myocardial protection.8,9 Recently, we have shown that
ATP-sensitive potassium-channel openers prevent
intracellular calcium accumulation during global
ischemia.10
To optimize our hyperpolarizing preservation solu-
tion, we formulated the composition to minimize intra-
cellular calcium overload, prevent myocyte swelling,
and promote anaerobic glycolytic flux. To avoid hyper-
kalemic depolarization, we designed the solution with
a physiologic potassium concentration of 5 mmol/L. To
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reduce sodium influx, thereby reducing calcium entry
through the sodium-calcium exchanger, we formulated
the solution with a low (intracellular) sodium concen-
tration and augmented it with a sodium channel block-
er, procaine. Elevated magnesium and micromolar cal-
cium concentrations were included because this ratio of
high magnesium and low calcium has also been associ-
ated with decreased intracellular calcium.11 The solu-
tion was enriched with lactobionate to chelate extracel-
lular calcium. The alkaline essential amino acid
histidine was included in high concentrations to buffer
intracellular protons because of its favorable pKa (6.8
at 25°C). Theoretically, histidine was added to prevent
intracellular sodium increase through the sodium-pro-
ton exchanger, subsequently reducing inward calcium
flux by the sodium-calcium exchanger. Previous work
has also implicated cellular swelling as an etiologic
factor in postcardioplegia myocardial stunning.12
Therefore, cardioprotective features that limit cellular
edema were built into the solution, including the
osmotic impermeants hydroxyethyl starch and manni-
tol and a low concentration of chloride.13,14 Histidine
was also included to stimulate glycolytic flux,15 with
high concentrations of glucose as a metabolic substrate
and insulin incorporated into the solution.
This study compared the cardioprotective effects of
the potassium-channel opener pinacidil administered in
our prototype preservation solution and the preserva-
tion solution without pinacidil (control) with the exten-
sively used University of Wisconsin (UW) solution
during prolonged ischemia.
Methods
Adult New Zealand White rabbits of either sex weighing 2.8
to 4.2 kg were used in this study. All animals received humane
care in American Association for Accreditation of Laboratory
Animal Care International–accredited (#00036), US
Department of Agriculture–registered (#52-R-007) facilities in
compliance with the “Principles of Laboratory Animal Care”
formulated by the National Society for Medical Research and
the “Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources and
published by the National Institutes of Health (National
Institutes of Health publication No. 85-23, revised 1985).
Animal preparation. Anesthesia was accomplished by an
intramuscular injection of acepromazine (1.0 mg/kg) and
xylazine (17.5 mg/kg), followed by ketamine (62.5 mg/kg). A
tracheotomy was performed, and mechanical ventilation
(model 683; Harvard Apparatus, S. Natick, Mass) was imple-
mented through an endotracheal tube with 100% oxygen.
Intravenous heparin was administered (2500 U) through an
ear vein. After heparinization, a sternotomy and rapid
cardiectomy were performed, and the heart was immediately
placed into a bowl of 4°C electrolyte solution (Plasma-Lyte;
Baxter Healthcare Corp, Deerfield, Ill). The aorta was sewn
to a cannula and rapidly attached to a crystalloid perfusion
column. A polyethylene vent was inserted through the apex of
the left ventricle.
A fluid-filled latex balloon was inserted into the left ventri-
cle and secured to the mitral valve anulus with a purse-string
suture (5-0 Prolene; Ethicon, Inc, Somerville, NJ). The intra-
ventricular balloon was connected with polyethylene tubing to
a pressure transducer (model P23ID; Gould Instrument
Systems, Inc, Valley View, Ohio) and amplifier (model 20-
4615-50; Gould). Two needle electrodes were placed on the left
ventricular (LV) epicardium to monitor the bipolar ventricular
electrogram. The signal was filtered between 0.05 and 1000
Hz. Two other electrodes were secured to the right atrial
appendage and connected to a pacemaker (model 5320;
Medtronic, Inc, Minneapolis, Minn). Heart rate was main-
tained at a constant rate of 200 beats/min. Pressure and elec-
trogram tracings were displayed continuously and digitized in
real time on a computer by means of a waveform recording
system (WinDAQ/400; DATAQ Instruments, Akron, Ohio) at a
sampling rate of 2000 Hz. A needle temperature probe (model
BAT 8; Bailey Instruments, Saddle Brook, NJ) was placed in
the right ventricle, which allowed myocardial temperature
monitoring (model TM147T; Electromedics, Inc, Parker,
Colo). The heart was enclosed in a plastic jacket to isolate from
temperature deviations in the air and was maintained at 37°C
by means of a water-jacketed beaker connected to a warm
water bath (model D1/L; Haake Co, Berlin, Germany).
Experimental preparation. A crystalloid-perfused
Langendorff apparatus was used for this study. The isolated
rabbit heart was suspended by means of an aortic cannula at
a column height of 70 cm. The column was perfused with
37°C Krebs-Henseleit buffered solution, which consisted of
the following: NaCl, 118.5 mmol/L; NaHCO3, 25.0
mmol/L; KCl, 3.2 mmol/L; KH2PO4, 1.2 mmol/L; MgSO4,
1.2 mmol/L; CaCl2, 2.5 mmol/L; and glucose, 5.5 mmol/L.
The Krebs-Henseleit solution was maintained at a strict pH
range between 7.42 and 7.48 by bubbling with a gas mixture
of 95% oxygen and 5% carbon dioxide. An ultrasonic flow
probe (model T101; Transonic Systems Inc, Ithaca, NY)
measured coronary flow in the perfusion column. A separate
70-cm cardioplegic arrest column was maintained at 4°C by
using water-cooling jackets. Water baths maintained the
temperatures of the perfusion and cardioplegic arrest
columns (models 800 and 9010; Fischer Scientific,
Pittsburgh, Pa).
Experimental protocol. The isolated rabbit hearts under-
went a 30-minute equilibration period after being mounted onto
the Langendorff circuit. Baseline LV pressure-volume curves
were then generated by inflating the LV balloon. Hearts were
excluded from the study if they were unable to generate pres-
sures of at least 60/10 mm Hg during baseline data acquisition.
Intracavitary LV pressures and bipolar LV electrograms were
recorded over 7 balloon volumes (BVs), each corresponding to
a fixed intracavitary LV end-diastolic pressure (EDP; 0, 2.5, 5,
10, 15, 20, and 25 mm Hg). Crystalloid column flow corre-
sponding to coronary flow was measured at each of these LV
pressures. After baseline data acquisition, the LV balloon was
deflated to generate an EDP of 2.5 mm Hg.
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After baseline data acquisition, hearts were arrested with
50 mL of hypothermic solution followed by 4 hours of
hypothermic storage in 50 mL of the same solution.
Twenty-four hearts were randomized to receive 1 of 3
preservative solutions: (1) prototype solution containing
0.5 mmol/L pinacidil, (2) prototype solution without
pinacidil as a control, and (3) UW solution (n = 8 for each
group). Hearts were stored for 4 hours at between 5°C and
10°C.
Each heart was returned to the Langendorff circuit and
reperfused for 60 minutes after storage. After reperfusion, LV
pressure-volume measurements were generated by means of
the same BVs used for baseline data acquisition. The per-
centage recovery of developed pressure (DP), diastolic pres-
sure-volume relationships, perfusate flow, and myocardial
edema was compared among treatment groups. After reperfu-
sion data acquisition, a portion of the LV apex was excised,
blotted, weighed (balance model TM 400; Mettler
Instruments, Corp, Hightstown, NJ), and dried (Isotemp
Oven model 625G; Fischer Scientific, Houston, Tex) until a
constant dry weight was reached. Myocardial edema was
expressed as the percentage of tissue water according to the
following equation: percentage tissue water = (wet weight –
dry weight)/wet weight × 100.
Solution preparation. Each component of the prototype
preservation solution (Table I) was added to a mixture of
deionized water and 12% pentastarch solution (Du Pont
Critical Care, Waukegan, Ill). Pinacidil (Leo Pharmaceutical
Products, Ltd, Ballerup, Denmark) was added from a stock
0.1 mol/L pinacidil dissolved in dimethyl sulfoxide.
Procaine, 5 mmol/L, was added to the pinacidil and control
solutions designated as cardioplegic flush. This was per-
formed by adding stock 1.0 mol/L procaine HCl dissolved in
dimethyl sulfoxide. The control solution contained a higher
mannitol concentration (70 mmol/L) than the pinacidil solu-
tion (25 mmol/L) to equilibrate higher osmolarity from the
addition of 0.5 mmol/L pinacidil in dimethyl sulfoxide. UW
solution was obtained as ViaSpan from Du Pont Merck
Pharmaceuticals (Wilmington, Del). UW solution was modi-
fied with the standard 0.016 g/L dexamethasone, 200,000
U/L penicillin, and 40 U/L insulin.
Data analysis. Digitized pressure waveforms were ana-
lyzed by means of commercial software programs (Spectrum
2.0; Triton Technology, Inc, San Diego, Calif; Microsoft
Excel 97; Microsoft Corp, Redmond, Wash).
End-systolic pressure. The end-systolic pressure (ESP) of a
beat was defined as the maximum point of the digitized pres-
sure waveform. The average ESP was calculated by averag-
ing 20 seconds of data. Average ESPs were obtained for each
BV at baseline and after reperfusion (postischemic). The ESP
versus BV data for baseline and postischemic data were fitted
to the linear ESP-volume relationship below by a least-
squares linear regression algorithm as follows: ESP = E
max
(BV) + k.
End-diastolic pressure. The EDP of a beat was defined as
the point at which the increase in slope of the pressure wave-
form exceeded a threshold of 0.5 mm Hg/ms. Average EDPs
were obtained for each BV at baseline and after reperfusion
3.1 mL/min to 29.8 ± 2.8 mL/min (P < .001). Hearts
stored in UW solution decreased from 45.0 ± 4.5
mL/min to 32.5 ± 4.7 mL/min (P < .001). Although
there was a trend that the greatest recovery of baseline
coronary flow was found in hearts exposed to pinacidil
(77.8% ± 3.0%) compared with those exposed to the
control (66.8% ± 2.4%) and UW solutions (70.9% ±
4.0%), the differences were not statistically significant-
ly different (P = .07). 
Postischemic systolic function. Hearts generated
mean DPs of 86 ± 4 mm Hg at baseline. The percentage
recovery of DP, calculated by the trapezoidal rule to
accommodate multiple isovolumic pressure-volume
points, was used to express systolic LV function. Hearts
arrested and stored in pinacidil solution exhibited signif-
icantly better recovery of DP (92.4% ± 4.5%) than con-
trol solution–stored (74.9% ± 3.4%, P = .01) or UW solu-
tion–stored hearts (66.7% ± 5.1%, P = .001; Fig 1).
Postischemic diastolic function. The recovery of
diastolic negative dP/dT (Fig 2) was best preserved in
hearts exposed to pinacidil solution (104.4% ± 10.2%)
compared with the control (80.2% ± 4.2%, P = .034)
and UW solutions (71.7% ± 7.0%, P = .015).
Postischemic diastolic slopes were higher than baseline
for the UW (P = .013) and control solutions (P = .047,
Table II). Postischemic diastolic slopes were not statis-
tically significantly different from baseline for hearts
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(postischemic). The EDP versus BV data were fitted to the
linear EDP-volume relationship by using a least-squares lin-
ear regression algorithm as follows: EDP = m (BV) + b. Mean
baseline and postischemic slopes were compared for each
group. The diastolic slope ratio was calculated by dividing the
baseline slope by the postischemic slope.
DP. DP in the left ventricle was calculated as the difference
between ESP and EDP. The DP versus BV values for baseline
and postischemic data were fitted to a linear pressure-volume
relationship by the following linear regression algorithm: DP
= ESP – EDP = (E
max
[BV] + k) – (m [BV] + b).
Recovery of DP. The recovery of DP, expressed as a per-
centage, was calculated as the ratio of the postischemic DP to
the baseline DP at the corresponding BV. The average per-
centage recovery of DP was calculated by a program devel-
oped in our laboratory by means of the trapezoidal rule.5
Minimal diastolic negative dP/dT. The diastolic minimal
negative dP/dT (dd
min) of a beat was calculated as the mini-
mal derivative of LV pressure during diastolic relaxation. The
mean dd
min was calculated by averaging 20 seconds of data.
Average dd
min values were obtained for each BV at baseline
and after reperfusion (postischemic). The dd
min versus BV
data for baseline and postischemic data were fitted to second-
order polynomial regressions. Each regression was integrated
to calculate the area under the curve (AUC), ranging from
minimum to maximum matched BV. To express the diastolic
contractile function over multiple LV volumes, we calculated
the percentage recovery of minimal diastolic negative dP/dT
as a ratio of the postischemic AUC divided by the baseline
AUC multiplied by 100.
Statistical analysis. Statistical analysis was performed by
means of the computer software SigmaStat (version 2.03;
Jandel Corp, San Rafael, Calif) and Microsoft Excel 97
(Microsoft Corp). Results are expressed as means ± SEM. A
paired t test was used to compare preischemic to postis-
chemic end points within groups. A 1-way analysis of vari-
ance (ANOVA) was used to compare multiple means. If a sta-
tistically significant difference was detected in the ANOVA,
individual comparisons between groups were made by a
Student-Newman-Keuls post test.
Results 
Perfusate flow. There were no differences in base-
line coronary flow rates among the 3 groups. The mean
flow rate for the preservative solutions during arrest
was 19.0 ± 1.0 mL/min for hearts perfused with UW
solution. This was significantly slower than flow rates
for hearts perfused with pinacidil and control solutions,
with mean flows of 28.7 ± 3.1 mL/min and 29.3 ± 2.9
mL/min, respectively. The flow rates of both prototype
solutions were statistically equivalent. Postischemic
coronary flows were significantly decreased compared
with baseline for each group. Hearts exposed to
pinacidil solution decreased from 43.6 ± 1.4 mL/min to
33.6 ± 1.6 mL/min after reperfusion (P < .001). Hearts
perfused with control solution decreased from 44.3 ±
Table I.  Composition of preservative solutions
Pinacidil Control UW
Component solution solution solution
Na (mmol/L) 55 55 30
K (mmol/L) 5 5 120
Cl (mmol/L) 5 5 —
Ca (mmol/L) 0.1 0.1 —
Mg (mmol/L) 10 10 5
H2PO4 (mmol/L) 5 5 25
SO4 (mmol/L) 10 10 5
Pinacidil (mmol/L) 0.5 — —
Procaine (mmol/L) 5 5 —
Histidine (mmol/L) 100 100 —
Pentastarch (g/L) 40 40 50
Insulin (IU/L) 100 100 40
Glucose (mmol/L) 10 10 —
Mannitol (mmol/L) 25 70 —
Lactobionate (mmol/L) 50 50 100
Adenosine (g/L) — — 1.34
Glutathione (g/L) — — 0.92
Allopurinol (g/L) — — 0.136
Penicillin (U/L) — — 200,000
Dexamethasone (g/L) — — 0.016
Osmolality (mOsm/kg) 400 365 315
pH 7.65 7.65 7.40
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exposed to the pinacidil preservation solution 
(P = .093). Diastolic compliance, expressed as base-
line/postischemic diastolic slope ratios (Fig 3), was
worst preserved in hearts stored in UW solution (0.67
± 0.07) compared with both the pinacidil (0.88 ± 0.05,
P = .041) and control solutions (0.87 ± 0.05, P = .021).
Myocardial tissue water. There were no significant
differences in percentage of tissue among the 3 experi-
mental groups (Table II).
Discussion
Hyperpolarized arrest has emerged as an alternative
approach to traditional depolarized arrest for prolonged
storage of donor organs used in heart transplantation.5,9
Hyperpolarized arrest avoids many of the problems asso-
ciated with hyperkalemic arrest by arresting the heart at
its natural resting state, the resting membrane potential.
Net intracellular ion fluxes are negligible at these poten-
tials because transmembrane ion gradients are balanced,
Fig 1. Postischemic systolic function expressed as the percentage of recovery of developed LV pressure of hearts
arrested and stored for 4 hours in pinacidil solution, control solution, and UW solution. Values are means ± SEM
(n = 8 for each group). There was a statistically significant difference determined by using 1-way ANOVA (P =
.001) versus UW solution (*P = .01) and versus control solution (†).
Fig 2. Postischemic diastolic function expressed as percentage of recovery of baseline diastolic negative dP/dT for hearts
arrested and stored for 4 hours in pinacidil solution, control solution, and UW solution. Values are means ± SEM (n = 8
for each group). Statistically significant differences determined by 1-way ANOVA (P = .015) versus UW solution (*P =
.034) and versus control solution (†).
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and few voltage-gated ion channels are open.4
Accordingly, energy-dependent ion pump activity and
metabolic demand are minimal. Studies have confirmed
myocardial oxygen consumption during hyperpolarized
arrest to be 50% less than depolarized arrest.8
Experimental evidence with several different pharma-
cologic agents has confirmed the benefits of hyperpolar-
ized arrest. Snabaitis and associates9 demonstrated that
hearts arrested with the sodium-channel blocker
tetrodotoxin maintained resting membrane potential dur-
ing hypothermic storage. These hearts exhibited better
postischemic function than did hearts arrested and stored
in hyperkalemic depolarizing solution.9 Hyperpolarized
arrest facilitated by the opening of ATP-sensitive potassi-
um channels by the cyanoguanidine pinacidil has also
provided better cardioprotection than depolarized
arrest.6,7 Hearts stored in pinacidil solution demonstrated
improved postischemic function compared with hyper-
kalemic depolarizing solutions, such as St Thomas’
Hospital solution, with cold ischemic times up to 2
hours.7 A recent study showed that these cardioprotective
effects occur with longer 4-hour ischemic periods.5
The pharmacologic benefits of pinacidil stem from
activation of an outward potassium that plays a role in the
cells’ normal response to ischemia.4 During ischemia,
channels associated with this potassium current are trig-
gered to open when intracellular levels of ATP decrease.
Under nonischemic conditions, these channels are closed.
Exogenous administration of pinacidil and other potassi-
um-channel openers open these ATP-sensitive channels.
This decreases membrane potential and the action poten-
tial duration, limiting calcium entry into the cytosol
through voltage-sensitive calcium channels.4 Pinacidil
also is a potent vasodilator that increases coronary flow in
both nonischemic and ischemic hearts.5 KATP-mediated
hyperpolarization of endothelial cells with subsequent
smooth muscle relaxation has been shown to underly
these vascular effects.16
Formulation of the pinacidil vehicle. Previous
work in our laboratory has documented the efficacy of
pinacidil administered in physiologic buffer (Krebs-
Henseleit) for long-term donor heart preservation.5
However, the clinical utility of these findings was lim-
ited because UW solution preserved postischemic con-
Fig 3. Postischemic diastolic compliance expressed as baseline/postischemic diastolic pressure-volume slope ratios
for hearts arrested and stored for 4 hours in pinacidil solution, control solution, and UW solution. Values are means
± SEM (n = 8 for each group). A ratio of 1 reflects no diastolic injury. Statistically significant differences deter-
mined by 1-way ANOVA (P = .041) versus pinacidil solution (§P = .021) and versus control solution (‡)
Table II. Baseline and postischemic LV compliance and percentage tissue water
Solution Baseline diastolic slope Postischemic diastolic slope Percentage tissue water
Pinacidil 107.3 ± 30.2 120.7 ± 33.2 83.5 ± 0.4
Control 117.5 ± 23.6 137.8 ± 28.2* 83.8 ± 0.5
UW 86.5 ± 9.0 138.2 ± 20.5* 84.1 ± 0.4
Values are means ± SEM.
*Statistically different from baseline diastolic slope (paired t test, P = .047 for control solution and P = .013 for UW solution).
mostly during reperfusion and rewarming. The precise
activity of the sodium-proton exchanger during
hypothermia also remains controversial. Although it
has been demonstrated that specific blockade of this
exchanger during ischemia results in improved post-
ischemic LV function, sodium-proton exchange block-
ade during reperfusion provides more robust improve-
ment of postischemic function.22
Several components of this solution were included to
protect against myocyte swelling. Because chloride has
been shown to function as a primary trigger for
myocyte swelling during hypothermic cardioplegic
arrest,12,14 the chloride concentration was minimized,
adding only a nominal concentration necessary for pro-
caine HCl addition (5 mmol/L). Hydroxyethyl starch
and lactobionate were added to increase extracellular
osmotic bulk.13 Mannitol was included for its well-
described free-radical scavenging properties23 in addi-
tion to increasing and balancing osmolarity.
Histidine also was added to promote anaerobic gly-
colytic flux.15 Ohkado and colleagues15 have shown that
the intracellular buffering action of histidine increased
the anaerobic end-products alanine and lactate, which
correlated with improved postischemic function. This
was facilitated when the metabolic substrate glucose was
included in the preservation solution along with insulin to
facilitate intracellular glucose entry. Inclusion of both
proton-buffering agent and glucose in preservation solu-
tions would promote anaerobic glycolysis and ATP pro-
duction to continue during ischemia.24
Recovery of systolic function. The control solution
effectively preserved postischemic systolic function
and was comparable with UW solution. The efficacy of
the control solution could be related to the aforemen-
tioned principles of its formulation. However, the pre-
cise contribution of each of the components is not
known. Furthermore, precise comparisons of the mech-
anism of action between these two solutions is complex
because of the numerous formulation differences.
The most important finding of this study was that the
addition of the potassium-channel opener pinacidil to the
control solution resulted in significantly improved postis-
chemic systolic function of hearts when compared with
UW solution. This finding supports our hypothesis that
hyperpolarized arrest through opening of KATP channels
may offer superior preservation of postischemic contrac-
tile function when compared with traditional hyper-
kalemic depolarized arrest. This supports previous find-
ings examining hyperpolarized cardioplegic arrest during
shorter periods of ischemia.6,12 It is not clear whether the
protective effect of pinacidil is mediated through the sar-
colemmal or mitochondrial KATP channels. Recent stud-
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tractile function better than pinacidil mixed in Krebs-
Henseleit solution. This prompted our formulation of a
new hyperpolarizing solution that would optimize
delivery of pinacidil and (1) reduce pathologic intracel-
lular calcium accumulation, (2) prevent cell swelling,
and (3) promote anaerobic glycolytic flux.
Intracellular calcium accumulation was hypothetical-
ly minimized during ischemia and reperfusion by
decreasing the availability of extracellular calcium and
reducing intracellular movement of extracellular calci-
um through voltage-sensitive calcium channels and
exchangers. To limit availability of extracellular calci-
um, we formulated the solution with a low (100
µmol/L) concentration of calcium. This low concentra-
tion was chosen to prevent the calcium paradox associ-
ated with calcium-free solutions.17 Lactobionate was
included because of its calcium-chelating activities.18
The lactobionate concentration was less (50 mmol/L)
than that of UW solution (100 mmol/L); however, this
lower concentration is equally efficacious in chelating
calcium.18 The potassium concentration was main-
tained at normal serum levels (5 mmol/L) to prevent
membrane depolarization, decreasing the ratio of open
voltage–sensitive L-type calcium channels. Because
high magnesium levels have been shown to displace
calcium from sarcolemmal binding sites, a high mag-
nesium level (10 mmol/L) was also included.19
Decreasing calcium entry during reperfusion by the
sodium-calcium exchanger was an additional strategy
in the formulation of the hyperpolarizing solution.
Under nonischemic and nonhypothermic conditions,
intracellular sodium is extruded through the sodium-
potassium adenosine triphosphatase. Hypothermia and
ischemia render this pump virtually nonfunctional.4
Intracellular sodium levels rise during ischemia,20
which are effectively extruded by the bidirectional
sodium-calcium exchanger during reperfusion. Efforts
to prevent intracellular sodium accumulation in our
solution focused on (1) decreasing the sodium concen-
tration gradient by providing a low (55 mmol/L) sodi-
um concentration, (2) preventing entry by blocking
sodium channels with procaine, and (3) decreasing
exchange of extracellular sodium for intracellular pro-
tons through the sodium-proton exchanger by robust
buffering of intracellular H+. Because the sodium-pro-
ton exchanger is the major compensatory mechanism
of myocytes to regulate increases in intracellular pro-
tons,21 the intracellular proton-buffering effect of histi-
dine was believed to be important.15
The activity of the Na+/Ca++ antiporter during
hypothermia is unknown. However, it is generally
agreed that sodium-calcium exchange likely occurs
ies have documented that activation of mitochondrial
KATP channels is cardioprotective.25 In this study we were
unable to discern which KATP channel is more important
because pinacidil nonselectively activates channels on
both sarcolemma and mitochondria.25
Recovery of diastolic function. The control solution
also effectively preserved postischemic diastolic func-
tion equivalent to UW solution. However, with the
addition of pinacidil, the hyperpolarizing solution was
able to significantly surpass the performance of hearts
stored in either UW solution or the control solution.
This preservation of active relaxation was assessed by
the percentage recovery of diastolic negative dP/dT
over several LV BVs. The negative dP/dT is influenced
by the rate at which calcium is removed from the con-
tractile proteins by the sarcoplasmic reticulum calci-
um–adenosine triphosphatase pump.26 Although direct
measurement is lacking, our results suggest more effi-
cient handling of calcium in hearts exposed to pinacidil
solution. This hypothesis is supported by the fact that
sarcoplasmic reticulum calcium–adenosine triphos-
phatase pumps have been shown to be sensitized by
other potassium-channel openers, such as nicorandil,
which correlated with enhanced lusitropy.27
Diastolic compliance was also best preserved by the
pinacidil solution. This was assessed by comparing
diastolic slope ratios over several LV BVs. Contrary to
preservation of active relaxation, optimized preserva-
tion of diastolic compliance was not solely attributable
to pinacidil. Both the pinacidil solution and the
pinacidil-free control solution preserved diastolic com-
pliance significantly better than UW solution. This may
have been attributable to their higher osmolarity.
Although all 3 solutions shared the large molecular
weight hydroxyethyl starch and lactobionate compo-
nents, both prototype solutions were fashioned with a
third impermeant, mannitol. This effectively raised the
osmolarity of pinacidil and control solutions higher
than UW solution (400 mOsm/kg and 365 mOsm/kg vs
315 mOsm/kg, respectively). The benefits of increased
osmolarity center around prevention of cellular
swelling and preservation of the extracellular vascular
space. Similar to our results, Starr and associates28
showed that diastolic compliance was a function of car-
dioplegic solution osmolarity. Myocardial tissue water
was inversely related to compliance in that study. The
finding that differences in the percentage of tissue
water were not revealed in this study may relate to
experimental protocol differences.28
Coronary flow. Hearts exposed to the pinacidil solu-
tion displayed improved postischemic coronary flow
compared with control solution and UW solution,
although these differences could be due to chance (P =
.07). Pinacidil has been shown to protect against the
endothelium-dependent vasodilatation impairment pro-
duced by ischemia through a KATP-dependent mecha-
nism.29 The protective effect of other potassium-chan-
nel openers has been recently related to preservation of
endothelium-derived hyperpolarizing factor–mediated
coronary vasorelaxation.16 The vasodilatory properties
of pinacidil produced by hyperpolarization of endothe-
lial cells and subsequent vascular smooth muscle relax-
ation also provide a means for facilitation of myocardial
perfusion during the reperfusion period. A relationship
between improved systolic function and coronary flow
has been previously documented by our group.5
However, the current study was unable to significantly
correlate the improved systolic function and coronary
flow with pinacidil solution. This may represent a type
II statistical error because of the small sample size.
Further studies will be needed to clarify this issue.
Limitations of the model. The crystalloid-perfused
Langendorff preparation was used in this study because it
allowed for analysis of interventions of the isolated heart
without humoral, neural, adrenergic, or anesthetic influ-
ences. The crystalloid preparation is less complicated
than a blood-perfused parabiotic animal preparation
because of its independence from the physiologic varia-
tions produced by the support animal. Moreover, for
long-term preservation of hearts, the maintenance of the
support animal becomes logistically impossible. The
findings of this study should be interpreted with caution
because the current preparation lacked blood perfusion
and the important dynamics of the intact organism. As
with any experimental results, these findings should be
extrapolated with caution to the clinical scenario.
An additional limitation of the study is based on the
lack of direct measurements of intracellular calcium
accumulation during ischemia and reperfusion. With
the novel pharmacologic milieu produced by the
hyperpolarizing solution during hypothermic storage,
the precise contribution of each component of the
pinacidil vehicle is unknown. An isolated comparison
of each of the individual components that differed
between the hyperpolarizing pinacidil and UW solu-
tions was not possible. However, UW solution does
provide a clinical frame of reference for comparison
in these studies. It is considered the gold standard for
donor heart preservation. These limitations will serve
as the focus for future studies.
Summary
A novel solution was formulated to preserve donor
hearts by using hyperpolarized arrest with the potassi-
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um-channel opener pinacidil. The delivery vehicle was
carefully composed to prevent intracellular calcium
accumulation and myocyte swelling and also promote
anaerobic glycolytic flux. This investigation demonstrat-
ed KATP channel–mediated enhancement of postischemic
systolic function, active diastolic properties, and coro-
nary flow by addition of pinacidil to the control solution.
Compared with UW solution, the pinacidil hyperpolariz-
ing solution resulted in significantly better myocardial
preservation of both systolic function and the diastolic
properties of the left ventricle. This study documents that
potassium-channel openers are effective for donor heart
preservation and have advantages over UW solution.
Future studies are needed to clarify whether these solu-
tions may prolong the period of safe myocardial protec-
tion in cardiac transplantation.
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